Tamoxifen: a caveat on the con side of the debate.
dc.contributor.author | Moser, S M | |
dc.date.accessioned | 2019-07-02T16:10:55Z | |
dc.date.available | 2019-07-02T16:10:55Z | |
dc.date.issued | 1993-04 | |
dc.identifier.issn | 0017-8594 | |
dc.identifier.pubmed | 8500988 | |
dc.identifier.uri | http://hdl.handle.net/10524/62578 | |
dc.language.iso | eng | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Breast Neoplasms/prevention & control | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Tamoxifen/adverse effects/therapeutic use | |
dc.title | Tamoxifen: a caveat on the con side of the debate. | |
dc.type | Clinical Trial | |
dc.type | Journal Article | |
dc.type.dcmi | Text | |
prism.number | 4 | |
prism.pagerange | 87-8, 102 | |
prism.publicationname | Hawaii medical journal | |
prism.volume | 52 |
Files
Original bundle
1 - 1 of 1